| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8410077 | ACROTECH | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US9200088 | ACROTECH | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US11020363 | ACROTECH | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
May, 2030
(6 years from now) | |
| US10864183 | ACROTECH | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
May, 2030
(6 years from now) | |
| US10940128 | ACROTECH | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same |
Jun, 2030
(6 years from now) | |
| US9493582 | ACROTECH | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(9 years from now) | |
| US10040872 | ACROTECH | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Jan, 2034
(10 years from now) | |
Evomela is owned by Acrotech.
Evomela contains Melphalan Hydrochloride.
Evomela has a total of 7 drug patents out of which 0 drug patents have expired.
Evomela was authorised for market use on 10 March, 2016.
Evomela is available in powder;intravenous dosage forms.
Evomela can be used as for high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.
The generics of Evomela are possible to be released after 30 January, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Mar 10, 2023 |
Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient
Market Authorisation Date: 10 March, 2016
Treatment: For high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma
Dosage: POWDER;INTRAVENOUS
EVOMELA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic